The benefits of HIV treatment: undetectable means you do not pass on the virus
Since its introduction in the 1990s, the main aim of combination antiretroviral therapy (ART) for HIV has been to halt the progression of the infection, maintaining the health of the HIV-positive person taking treatment. In addition to this, the impact of treatment as prevention has been well described.
Systematic review on the prevention and control of blood-borne viruses in prison settings
The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, with a focus on the countries of the European Union (EU) and the European Economic Area (EEA).
Guidance in brief: Prevention and control of blood-borne viruses in prison settings
This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.
Preventing blood-borne viruses in prison settings: ECDC and EMCDDA Guidance
In their joint public health guidance published today at AIDS 2018, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) outline evidence-based and effective measures to help prevent and control the transmission of blood-borne viruses in prison settings.
Public health guidance on prevention and control of blood-borne viruses in prison settings
This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.
Lymphogranuloma venereum - Annual Epidemiological Report for 2016
Lymphogranuloma venereum (LGV) is a systemic STI caused by Chlamydia trachomatis serovars L1, L2, or L3. In 2016, 2 043 cases of LGV were reported in 22 countries.
Hepatitis B - Annual Epidemiological Report for 2016
In 2016, 30 EU/EEA Member States reported 29 307 cases of hepatitis B virus (HBV) infection, corresponding to a crude rate of 5.5 cases per 100 000 population.
Hepatitis C - Annual Epidemiological Report for 2016
In 2016, 33 860 cases of hepatitis C were reported in 29 EU/EEA Member States, corresponding to a crude rate of 7.4 cases per 100 000 population.